Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Gorovits

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
Bioanalysis|November 24, 2012
Tissue bioanalysis of biotherapeutics and drug targets to support PK/PDHendrik Neubert, Scott Fountain, Lindsay King, et al.
The AAPS Journal|January 1, 2015
Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidanceBrian Booth, Mark E Arnold, Binodh DeSilva, et al.
Blood|November 15, 2003
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignanciesJohn F DiJoseph, Douglas C Armellino, Erwin R Boghaert, et al.
Journal of Immunological Methods|February 16, 2008
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsEugen Koren, Holly W Smith, Elizabeth Shores, et al.
The AAPS Journal|January 6, 2026
Assessment of Immune Responses Against AAV Encoded Transgene ProductsBoris Gorovits, Mitra Azadeh, Michele Fiscella, et al.
The AAPS Journal|May 13, 2022
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity PlatformGregor P Lotz, Karin Benstein, Karien Bloem, et al.
Frontiers in Immunology|June 6, 2025
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity PlatformJoanna Grudzinska-Goebel, Karin Benstein, Karien Bloem, et al.
Bioanalysis|December 24, 2014
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity)Lauren Stevenson, Lakshmi Amaravadi, Heather Myler, et al.
Bioanalysis|December 23, 2014
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input)Dawn Dufield, Hendrik Neubert, Fabio Garofolo, et al.
Bioanalysis|December 5, 2015
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity)Lakshmi Amaravadi, An Song, Heather Myler, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
Bioanalysis|November 24, 2012
Tissue bioanalysis of biotherapeutics and drug targets to support PK/PDHendrik Neubert, Scott Fountain, Lindsay King, et al.
The AAPS Journal|January 1, 2015
Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidanceBrian Booth, Mark E Arnold, Binodh DeSilva, et al.
Blood|November 15, 2003
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignanciesJohn F DiJoseph, Douglas C Armellino, Erwin R Boghaert, et al.
Journal of Immunological Methods|February 16, 2008
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology productsEugen Koren, Holly W Smith, Elizabeth Shores, et al.
The AAPS Journal|January 6, 2026
Assessment of Immune Responses Against AAV Encoded Transgene ProductsBoris Gorovits, Mitra Azadeh, Michele Fiscella, et al.
The AAPS Journal|May 13, 2022
When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity PlatformGregor P Lotz, Karin Benstein, Karien Bloem, et al.
Frontiers in Immunology|June 6, 2025
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity PlatformJoanna Grudzinska-Goebel, Karin Benstein, Karien Bloem, et al.
Bioanalysis|December 24, 2014
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity)Lauren Stevenson, Lakshmi Amaravadi, Heather Myler, et al.
Bioanalysis|December 23, 2014
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input)Dawn Dufield, Hendrik Neubert, Fabio Garofolo, et al.
Bioanalysis|December 5, 2015
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity)Lakshmi Amaravadi, An Song, Heather Myler, et al.
Pageof 8